zinc finger protein 257Genealiases: BMZF-4 · BMZF4
Q-omics provides the consensus-scored ZNF257 profile across patient tissues and cancer cell-line models. ZNF257 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF257 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF257 RNA expression shows 16,878 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where ZNF257 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF257 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF257 survival associations across molecular data types. ZNF257 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF257 RNA expression–survival associations across cancer types. High ZNF257 expression shows unfavorable associations in READ, but favorable associations in HNSC, UVM, MESO, LUAD and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF257 RNA expression.
This table summarizes ZNF257 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF257. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF257 shows lower tumor expression in THCA, COAD, KIRC and READ and higher tumor expression in LIHC and BRCA. The THCA box plot shows higher ZNF257 RNA expression in normal versus tumor tissue (log2 FC = −0.854, t-test p < 0.001).
This table shows molecular features associated with ZNF257 in patient tissues and cancer cell lines. In patient samples, ZNF257 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF257 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
